https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://retinalphysician.com/media/uvohm5dy/may25_cover.jpg
Ophthalmology Management
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://retinalphysician.com/media/npjdtl1w/cp_november_cover.jpg
Corneal Physician
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://retinalphysician.com/media/n2nnmblv/cover_march25.jpg
Glaucoma Physician
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://retinalphysician.com/media/mvqdq2hc/nrp_cover_october_2024.jpg
New Retinal Physician
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://retinalphysician.com/media/fu1cgtla/op_0425_cover.jpg
Ophthalmic Professional
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://retinalphysician.com/media/aqbjxwjw/pp-cover.jpg
Presbyopia Physician
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://retinalphysician.com/media/x1cbp0cz/cover_may25_web.jpg
Retinal Physician
Friday, May 23, 2025
Investigators at the National Institutes of Health engineered a surgical clamp that stabilizes intraocular pressure during the sequential implantation of 2 tissue patches while minimizing trauma to surrounding tissue.
By Sarah Fackler
Thursday, May 22, 2025
This is the third approved indication for the ranibizumab injection, which is delivered via the refillable port delivery system.
Tuesday, May 13, 2025
Preliminary data on an investigational treatment for Leber congenital amaurosis prompts the FDA to grant the Regenerative Medicine Advanced Therapy designation.
Tuesday, May 13, 2025
Zervimesine reduced lesion growth in patients with late-stage dry AMD by nearly 30% in a phase 2 trial.
Friday, May 9, 2025
The extension trial followed subjects that completed the pivotal LIGHTSITE III trial and resumed treatment for 13 months with the Valeda Light Delivery System.
Thursday, May 8, 2025
Data were presented from Alkeus Pharmaceuticals’ phase 2 SAGA clinical study in GA secondary to AMD.
Tuesday, May 6, 2025
GAL-101, an oral therapy designed to target misfolded Aβ proteins, is shown to be well tolerated in first stage of trial.
Tuesday, May 6, 2025
The VAN-2401 study will assess the safety and durability of a single-dose gene therapy for treatment of neovascular age-related macular degeneration.
Monday, May 5, 2025
The move accelerates the company's AI-powered imaging innovation in eye care.
Monday, May 5, 2025
OcuSciences, Inc. announced at ARVO that the FDA has granted marketing clearance for its flagship device, the OcuMet Beacon, a confocal scanning ophthalmoscope designed for infrared and autofluorescence imaging of the retina.
Thursday, May 1, 2025
The Regenerative Medicine Advanced Therapy designation supports the development of this long-duration anti-VEGF gene therapy as a treatment for DME.
Wednesday, April 30, 2025
Prevent Blindness said the goal is to educate patients on various forms of inherited retinal diseases and the importance of genetic testing.
Monday, April 28, 2025
A new approach could offer a potential treatment for AMD and other retinal disorders.
Monday, April 28, 2025
Study finds that protein markers in aqueous humor could help identify high-risk uveal melanomas.
Friday, April 25, 2025
According to Alcon, the systems feature many first-to-market technologies designed to deliver transformative surgical innovation for cataract and vitreoretinal surgery, including Unity 4D Phaco, HYPERVIT 30K and the advanced Unity Intelligent Fluidics system.
Thursday, April 24, 2025
The agency did not agree with Regeneron’s proposal to add dosing intervals greater than every 16 weeks, the maximum interval currently indicated for aflibercept 8 mg injections.
Thursday, April 17, 2025
The agency has initiated priority review of the anti-VEGF agent as a treatment for macular edema secondary to retinal vein occlusion.
Thursday, April 17, 2025
Oculis and EURETINA will once again fund the Ramin Tadayoni Award, which supports innovation in retina. Applications for the prize are now open.
Wednesday, April 16, 2025
The agreement clears the way for Yesafili, an FDA-approved aflibercept biosimilar, to be commercialized in the United States.
Wednesday, April 16, 2025
Atsena Therapeutics received the designation for ATSN-201, a therapy intended to treat X-linked retinoschisis.
Friday, April 11, 2025
The FDA sets an August 2025 PDUFA target to review the application of ophthalmic bevacizumab for wet AMD.
Thursday, April 10, 2025
Two studies in the company's phase 3 DIAMOND program are evaluating a novel eye drop for diabetic macular edema.
Tuesday, April 8, 2025
Preliminary results in a pediatric patient who underwent gene therapy to treat a form of Leber congenital amaurosis show improved vision and no safety issues.
Thursday, April 3, 2025
Unity Biotechnology reports that treatment with UBX1325 resulted in vision gains comparable to aflibercept at weeks 24 and 36 in a difficult-to-treat patient population.
Monday, March 31, 2025
Top-line data from the phase 3 trials of sozinibercept showed that the nAMD treatment failed to meet its primary BCVA endpoints in both studies.
Monday, March 24, 2025
CMS will provide separate payment for the drug in surgical settings starting April 1.
Monday, March 24, 2025
The trial did not meet its primary endpoint of mean change in best-corrected visual acuity (BCVA) from baseline to week 52.
Thursday, March 20, 2025
The company will retain the Kalaris name, and will continue enrolling its phase 1 nAMD trial of TH103, a novel anti-VEGF agent.
Monday, March 17, 2025
The implant is now approved as a treatment for chronic noninfectious uveitis affecting the posterior segment of the eye in addition to DME.
Thursday, March 13, 2025
Atsena Therapeutics's ATSN-201 is aimed at treating X-linked retinoschisis, a rare inherited disease.
Tuesday, March 11, 2025
The 5-year plan should ensure continued production of the preservative-free corticosteroid, which was unavailable in the US between 2022 and 2024.
Friday, March 7, 2025
The enhanced dataset will help clinicians detect and manage eye diseases at an earlier stage.
Thursday, March 6, 2025
In a recent meeting with the FDA, the company confirmed key elements of the trials planned for its sustained-release TKI therapy.
Thursday, March 6, 2025
Neurotech’s ocular insert Encelto aims to slow vision loss in patients with this degenerative retinal disease.
Tuesday, March 4, 2025
The pivotal trial is designed to evaluate the efficacy and safety of Ixo-vec, an investigational gene therapy, in patients with neovascular AMD.
Tuesday, March 4, 2025
The company has resubmitted its BLA for ONS-5010, an ophthalmic formulation of bevacizumab, with data from the recently completed NORSE EIGHT trial.
Tuesday, March 4, 2025
The paper reports pre-specified and post hoc analyses of angiographic predictors of response to sozinibercept combination therapy with ranibizumab in treatment-naïve patients with wet AMD.
Friday, February 28, 2025
The goal of the annual observance is to provide employers and employees with important information to help keep eyes safe and healthy at work.
Thursday, February 27, 2025
The campaign validates Ophthea's commercial-scale drug manufacturing process, in preparation for a potential BLA filing for sozinibercept in wet AMD.
Thursday, February 27, 2025
Masked analysis shows participants receiving oral zervimesine for at least 6 months experienced slower lesion growth than participants receiving placebo.
Monday, February 24, 2025
In this first-in-human interventional study, 4 legally blind children gained visual acuity following delivery of gene therapy.
Friday, February 21, 2025
The Eye Health Summit, a new global patient-centered event dedicated to integrative eye health, will take place May 1-7 as a free hybrid event.
Friday, February 21, 2025
The company says the device will enable screenings for retinal diseases in various health care and retail settings.
Tuesday, February 18, 2025
The initiative, taking place February 24 to March 2, is intended to provide education and support for families of children with retinopathy of prematurity.
Tuesday, February 18, 2025
COAST is a phase 3 pivotal trial investigating sozinibercept in combination with aflibercept as a treatment for wet AMD.
Tuesday, February 18, 2025
The first patient has been dosed in the pediatric cohort of the phase 1/2 trial of OPGx-LCA5, with initial data anticipated by Q3 2025.
Saturday, February 15, 2025
The next-generation MonacoPro system integrates ultrawidefield imaging with improved diagnostic support.
Thursday, February 13, 2025
The phase 3 QUASAR study finds the extended dosing intervals effective for macular edema secondary to retinal vein occlusion.
Thursday, February 13, 2025
4D Molecular Therapeutics recently reported 52-week data from a phase 2b study indicating that the therapy demonstrated stable vision outcomes and reduced treatment burden.
Thursday, February 13, 2025
The update removes limitations on duration of dosing for the GA treatment.
Thursday, February 13, 2025
Five-year data from the REFLECT trial of Lumevoq demonstrate long-term efficacy and safety.
Thursday, February 6, 2025
The free, online event at 7 p.m. ET on March 13, will review several topics, including: Viral delivery systems, surgical techniques, current clinical trials and endpoints, inflammation management, and future directions.
Wednesday, February 5, 2025
Six-month data from the phase 2 VERONA trial shows Duravyu extended treatment intervals and improved vision for diabetic macular edema patients.
Tuesday, February 4, 2025
Genentech’s refillable implant is the first continuous-delivery treatment that offers an alternative to regular eye injections to treat diabetic macular edema.
Monday, February 3, 2025
Origin matters for this hereditary ocular cancer because researchers found that male and female copies of the mutation are associated with different disease trajectories, and so would likely influence physicians' treatment recommendations.
Monday, February 3, 2025
EyeXchange Solutions connects experienced and emerging surgeons across cataract, glaucoma, and retina specialties to share insights, refine techniques, and address complex cases.
Thursday, January 30, 2025
Norlase has announced the immediate commercial launch and FDA 510(k) clearance and CE Mark for LYNX, the company’s pattern scanning laser indirect ophthalmoscope.
Thursday, January 30, 2025
AI Optics' Sentinel Camera is a handheld retinal imaging system that captures high-quality images of the human eye, and is designed to be easy to use and support non-dilated imaging.
Thursday, January 30, 2025
PulseSight Therapeutics announced it has submitted a Clinical Trial Authorization to France's regulatory agency for PST-611, a first-in-class non-viral vectorized therapy for the treatment of dry age-related macular degeneration and geographic atrophy.
Thursday, January 30, 2025
Ocular Therapeutix has outlined the clinical progress across its registrational program for Axpaxli in wet age-related macular degeneration (wet AMD), plans to advance Axpaxli in non-proliferative diabetic retinopathy (NPDR), and the company’s strategic outlook for 2025 in its presentation at the 43rd Annual J.P. Morgan Healthcare Conference.
Thursday, January 30, 2025
According to Harrow, the Harrow Cares program ensures seamless enrollment, rapid access to therapy, and personalized support, enabling retina providers to confidently utilize Iheezo and Triesence in their practices.
Wednesday, January 22, 2025
The designation is for the company's AAV8-RK-RetGC program for the treatment of patients with Leber congenital amaurosis due to GUCY2D mutations (LCA1). It makes the fourth Rare Pediatric Disease Designation MeiraGTx has received for inherited retinal diseases.
Tuesday, January 21, 2025
Fast Track Designation represents an objective assessment by the FDA for the potential of NPI-001 tablets as a treatment for retinitis pigmentosa, the company said.
Wednesday, January 15, 2025
Patients with Leber hereditary optic neuropathy due to the MT-ND4 gene variant demonstrated sustained bilateral improvement in visual acuity and a favorable safety profile 5 years after treatment.
Wednesday, January 15, 2025
Through the collaboration, City Therapeutics will leverage its next-generation RNAi engineering technologies to develop a novel RNAi clinical candidate toward a specific disease target for intravitreal administration.
Wednesday, January 15, 2025
In a US clinical trial of five patients with bilateral geographic atrophy, sustained-release intravitreous implants of K8 were well tolerated, with no drug-related ocular or systemic serious adverse events.
Tuesday, January 14, 2025
Samsara Vision reported intermediate-term visual and safety outcomes of a study of the SING IMT in patients 6 months post-surgery.
Tuesday, January 14, 2025
The 3E10 vg/eye dose demonstrated notable efficacy, achieving sustained visual acuity gains.
Monday, January 13, 2025
With innovative therapies addressing glaucoma and geographic atrophy currently in development, the acquisition of Whitecap Bioscience's strengthens B + L’s expanding clinical-stage pipeline.
Tuesday, January 7, 2025
Recently published results of a phase 1 study support its potential in combination with aflibercept.
Tuesday, January 7, 2025
The deal allows each company to focus on strengths.
Monday, January 6, 2025
Monday, January 6, 2025
Monday, January 6, 2025
SolidddVision’s vision correction technology can improve sight for patients with macular degeneration and other conditions.
Monday, January 6, 2025
ACUITY trial reveals potential to improve retinal structure and vision.
Monday, January 6, 2025
The deal to acquire the Italian company expands Essilor’s medical technology portfolio.
Monday, January 6, 2025
The phase 2 study will examine GAL-101’s potential to slow the growth of geographic atrophy lesions.
